Keyphrases
Acetylcholinesterase Inhibitors (AChEI)
100%
Allied Health
12%
Alzheimer's Disease
100%
Alzheimer's Disease Patient
37%
Attrition Rate
12%
Behavioral Symptoms
100%
Beneficial Effects
12%
Clinical Significance
12%
Cochrane
12%
Confidence Interval
50%
Cumulative Index
12%
Data Extraction
12%
Data Synthesis
12%
Dementia with
12%
Donepezil
12%
English Language
12%
Evidence-based
12%
Galantamine
12%
Health Literature
12%
Human Studies
12%
Inclusion Criteria
12%
Intention-to-treat Analysis
12%
MEDLINE
12%
Meta-analysis
100%
Mild Alzheimer's Disease
12%
Neuropsychiatric Inventory Questionnaire (NPI-Q)
12%
Neuropsychiatric Symptoms of Dementia
100%
Nursing
12%
Placebo
12%
Psychological Symptoms
100%
Randomized Placebo-controlled Trial
12%
Review Manager
12%
Rivastigmine
12%
Severe Alzheimer's Disease
25%
Standardized Mean Difference
12%
United States Preventive Services Task Force
12%
Weighted Mean Difference
37%
Nursing and Health Professions
Alzheimer's Disease
100%
Cholinesterase Inhibitor
100%
CINAHL
20%
Confidence Interval
80%
Data Extraction
20%
Data Synthesis
20%
Donepezil
20%
Galantamine
20%
Intention to Treat Analysis
20%
Meta Analysis
100%
Patient with Alzheimer's Disease
40%
Placebo
40%
Practice Guideline
20%
Preventive Health Service
20%
Rivastigmine
20%
Neuroscience
Acetylcholinesterase Inhibitor
100%
Alzheimer's Disease
100%
Donepezil
14%
Galantamine
14%
Meta-Analysis
100%
Neuropsychiatry
14%
Placebo
28%
Rivastigmine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Cholinesterase Inhibitor
100%
Donepezil
14%
Galantamine
14%
Human Study
14%
Placebo
28%
Rivastigmine
14%